View Post

Foscarnet prophylaxis reduces severity but does not prevent HHV-6 encephalitis

In All, Encephalitis & Encephalopathy, Transplant Complications, Treatments - Antiviral by Kristin Loomis

A Japanese trial of foscarnet prophylaxis in cord blood transplant patients was successful in reducing severity and mortality as well as suppressing high viral loads, but it failed to prevent encephalitis. The authors note that the blood brain barrier must be inflamed to allow effective penetration of the drug into the central nervous system and speculate that the prophylaxis may have protected the meninges.

View Post

2019 Conference

In All by Sheryl Lunsford

The 11th International Conference on HHV-6 & 7 will be held in beautiful Quebec City, Canada June 23–26, 2019.

View Post

HHV-6B reactivates first, proceeds to end organ disease faster in transplant patients

In All, Gastrointestinal, Transplant Complications by Kristin Loomis

Investigators at Fred Hutch Cancer Research Center found that HHV-6B is the first DNA virus to reactivate at a median of 3 weeks, compared to CMV, EBV and Adenovirus at 5-6 weeks. HHV-6B also peaked rapidly, unlike other DNA viruses that took 3-6 weeks to reach peak viral load. HHV-6B reactivation resulted in increased mortality after 100 days.

View Post

Ancient iciHHV-6 genomes vary considerably from community strains, but still capable of reactivation

In All, ciHHV-6 by Kristin Loomis

British researchers used molecular dating methods to determine that most strains of iciHHV-6 come from a small number of ancient human ancestors; the youngest found lived over 24,000 years ago. These ancient strains vary considerably from modern non-inherited strains of HHV-6A and appear just as likely to activate as their more modern cousins.